A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

Exclusion Criteria

• •Part 1 Healthy volunteers :
• •History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction.
• •Use of any prescription drugs, herbal supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing.
• •Part 2 Patients with atopic dermatitis:
• •History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction.
• •History of abnormal skin reactivity to UV light. Unusual exposure to UV light in the previous 3 weeks to study start (screening), including tanning and sun beds.
• •Pregnant or nursing (lactating) women.
• •Women of child-bearing potential must use highly effective contraception (as further defined in study protocol)
• •Use of topical prescription treatment for eczema within 1 week prior to initial dosing of topical corticosteroids (TCS).
• •Recent previous treatment with systemic treatment including phototherapy. A washout period will be required for such patients to be eligible to participate in the trial.
• •Part 3 Patients with Netherton Syndrome:
• •History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or history of serious allergic reaction.
• •History of abnormal skin reactivity to UV light. Unusual exposure to UV light in the previous 3 weeks to study start (screening), including tanning and sun beds.
• •Pregnant or nursing (lactating) women.
• •Women of child-bearing potential must use highly effective contraception (as further defined in study protocol)
• •Use of topical prescription treatment within 2 week prior to initial dosing of study drug.
• •Recent previous treatment with systemic treatment. A washout period will be required for such patients to be eligible to participate in the trial.